Literature DB >> 30831622

[Chinese guidelines for diagnosis and treatment of myelodysplastic syndromes (2019)].

.   

Abstract

Entities:  

Year:  2019        PMID： 30831622     DOI： 10.3760/cma.j.issn.0253-2727.2019.02.001

Source DB:  PubMed          Journal:  Zhonghua Xue Ye Xue Za Zhi        ISSN： 0253-2727


× No keyword cloud information.
  12 in total

1.  [Mean corpuscular volume ≤100 fl was an independent prognostic factor in patients with myelodysplastic syndrome and bone marrow blast<5 percent].

Authors:  Z X Shi; T J Qin; Z F Xu; H J Huang; B Li; S Q Qu; N B Hu; L J Pan; D Liu; Y N Cai; Y D Zhang; Z J Xiao
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-01-14

2.  [Clinical analysis of VAF value difference of gene mutation in myelodysplastic syndrome].

Authors:  X D Lyu; Y W Li; Z Guo; J Y Hu; R H Fan; Y P Song
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-10-14

3.  [Clinical features and prognostic analysis of myelodysplastic syndromes patients with U2AF1 mutation].

Authors:  C Hou; S H Jiang; H J Shen; Z X Ding; M Miao; S N Chen; Y Xu; D P Wu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-01-14

4.  [Analysis of clinical characteristics, treatment response rate and survival of 77 myelodysplastic syndrome patients with del (5q) syndrome].

Authors:  D Liu; Z F Xu; T J Qin; C W Li; N B Hu; L J Pan; S Q Qu; B Li; Z J Xiao
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-11-14

5.  [How I treat myelodysplastic syndromes with allogeneic hematopoietic stem cell transplantation].

Authors:  E L Jiang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2021-01-14

6.  [Guideline of the diagnosis and treatment of chronic myelomonocytic leukemia (2021)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2021-01-14

7.  [Efficacy and safety of generic azacitidine in Chinese patients with higher-risk myelodysplastic syndromes: a multicenter, prospective, single-arm study].

Authors:  H G Zhao; F Liu; T J Qin; H Bai; M Hou; K Yu; Y Hu; L Liu; Y Li; L Yu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-10-14

8.  [Outcomes of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome without excess blasts].

Authors:  Y Yu; X H Zhang; Y Wang; H Chen; W Han; Y Chen; Y Y Zhang; Y Y Chen; X D Mo; H X Fu; C H Yan; Y Q Sun; F R Wang; J Z Wang; K Y Liu; X J Huang; L P Xu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-10-14

9.  [Lenalidomide for myelodysplastic syndrome with excess blasts with germline DDX41 mutation: a case report and literatures review].

Authors:  J Chen; S Q Qu; T J Qin; Z J Xiao; Z F Xu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-10-14

10.  [Molecular features and prognostic value of RAS mutations in patients with myelodysplastic syndromes].

Authors:  H J Huang; B Li; T J Qin; Z F Xu; N B Hu; L J Pan; S Q Qu; D Liu; Y D Zhang; Z J Xiao
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.